Clinical Trial Update: Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the combination of F16-IL2 and doxorubicin in patients with advanced solid tumors, including breast cancer, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Doxorubicin (doxorubicin)
• F16IL2 (F16-IL2)

Snippet

Sponsor: Philogen S.p.A. | Conditions: Advanced Solid Tumor, Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED